Physician profile
Karissa E Tan
NPI 1114270899
$2,769.88
in general payments reported to CMS, 2019-2025
32 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $788 · 2022: $1,661 · 2023: $47.70 · 2024: $49.06 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $222 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $221.73 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $364.12 | 2021-2022 | |
| Daiichi Sankyo INC. | $273.59 | 2021-2022 | |
| Janssen Biotech, INC. | $231.66 | 2021-2025 | Talvey, Tecvayli, Darzalex |
| Novartis Pharmaceuticals Corporation | $208.32 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $195.70 | 2021-2022 | |
| Incyte Corporation | $178.94 | 2021-2022 | |
| Celgene Corporation | $152.81 | 2022 | |
| Sobi, INC | $143.60 | 2022-2025 | |
| Genzyme Corporation | $141.08 | 2021-2022 | |
| Pfizer INC. | $125.86 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $74.70 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $66.47 | 2023-2024 | Libtayo |
| Eisai INC. | $66.45 | 2022 | |
| Seagen INC. | $59.19 | 2021-2022 | |
| Taiho Oncology, INC. | $56.54 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $46.92 | 2022 | |
| Array Biopharma INC | $41.17 | 2022 | |
| Astellas Pharma US INC | $34.94 | 2022 | |
| Pharmacosmos Therapeutics INC. | $34.06 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.41 | 2022 | |
| Merck Sharp & Dohme LLC | $28.76 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $26.30 | 2022 | |
| Global Blood Therapeutics, INC. | $25.58 | 2022 | |
| Epizyme, INC. | $23.39 | 2022 | |
| Rigel Pharmaceuticals, INC. | $21.26 | 2022 | |
| Alexion Pharmaceuticals, INC. | $18.69 | 2022 | |
| Chiesi USA, INC. | $18.16 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.02 | 2022 | |
| Jazz Pharmaceuticals INC. | $15.86 | 2022 | |
| Emd Serono, INC. | $15.69 | 2021 | |
| Genentech USA, INC. | $15.61 | 2022 | |
| Myovant Sciences INC. | $15.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karissa Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.